Form 4: Arcus Biosciences CAO Sells Shares Under 10b5-1 Plan

Arcus Biosciences' Chief Accounting Officer, Alexander Azoy, sold 2,831 shares of common stock at $13 per share, pursuant to a Rule 10b5-1 trading plan.

Summary

• Alexander Azoy, Chief Accounting Officer of Arcus Biosciences, Inc. (RCUS), reported a sale of common stock.
• A total of 2,831 shares of Arcus Biosciences common stock were disposed of.
• The transaction occurred on September 29, 2025, at a price of $13 per share.
• Following this transaction, Alexander Azoy beneficially owns 27,363 shares of common stock.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted by the reporting person on June 6, 2025.

Sentiment

Score: 4

Explanation: The sale of shares by a Chief Accounting Officer is generally perceived as a slightly negative signal. However, the fact that it was executed under a pre-arranged Rule 10b5-1 trading plan mitigates the negative sentiment, suggesting it's for personal financial planning rather than a reaction to new material non-public information.

Negatives

• Chief Accounting Officer Alexander Azoy sold 2,831 shares of Arcus Biosciences common stock, which can be perceived as a negative signal by investors, despite being part of a pre-arranged plan.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight reduction in management's direct equity exposure, though the 10b5-1 plan suggests a pre-planned, non-discretionary transaction.

Key Dates

Keywords

Arcus Biosciences, RCUS, Alexander Azoy, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Accounting Officer